PDS Biotech Q1 net loss $8.5M; Phase 3 VERSATILE-003 trial underway

PDS Biotechnology Corp

2025-Q1 EPS reported -$0.21

Net loss of $8.5M ($0.21 per share) in Q1 2025 vs $10.6M ($0.30) in Q1 2024; R&D expenses fell to $5.8M.
Cash and equivalents $40M as of March 31, 2025; includes $11M from Feb 2025 registered direct offering with warrants for up to $11M more.
VERSATILE-003 Phase 3 trial initiated for Versamune HPV + pembrolizumab in HPV16-positive HNSCC; targets ~350 patients with 2:1 randomization.
FDA cleared IND for Versamune MUC1 + PDS01ADC in metastatic colorectal cancer; NCI to lead Phase 1/2 under CRADA.
Three Versamune HPV abstracts selected for presentation at 2025 ASCO Annual Meeting (May 30-June 3).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.